Celgene to stop blood cancer trial due to high death rates

Thu Jul 18, 2013 8:23am EDT

(Reuters) – Celgene Corp said it will stop a late-stage trial of its blood cancer drug Revlimid after it observed a higher number of deaths in patients taking the drug compared to those on another treatment.

Revlimid is Celgene’s…
Celgene to stop blood cancer trial due to high death rates

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: